Chemung Canal Trust’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$464K Sell
19,262
-1,110
-5% -$29K 0.09% 89
2026
Q1
$572K Sell
20,372
-525
-3% -$14K 0.12% 87
2025
Q4
$520K Sell
20,897
-2,939
-12% -$74.1K 0.1% 92
2025
Q3
$607K Sell
23,836
-4,560
-16% -$113K 0.12% 88
2025
Q2
$688K Sell
28,396
-6,919
-20% -$161K 0.14% 80
2025
Q1
$895K Sell
35,315
-17,180
-33% -$450K 0.2% 79
2024
Q4
$1.39M Sell
52,495
-153,908
-75% -$4.17M 0.29% 68
2024
Q3
$5.97M Buy
206,403
+139,550
+209% +$4.07M 1.21% 27
2024
Q2
$1.87M Buy
66,853
+5,488
+9% +$151K 0.36% 61
2024
Q1
$1.7M Buy
61,365
+8,425
+16% +$234K 0.33% 63
2023
Q4
$1.52M Sell
52,940
-13,251
-20% -$401K 0.32% 57
2023
Q3
$2.2M Sell
66,191
-2,979
-4% -$105K 0.5% 52
2023
Q2
$2.54M Sell
69,170
-1,920
-3% -$74.7K 0.54% 51
2023
Q1
$2.9M Sell
71,090
-87,541
-55% -$3.78M 0.67% 47
2022
Q4
$8.13M Sell
158,631
-2,230
-1% -$107K 1.85% 15
2022
Q3
$7.04M Buy
160,861
+2,057
+1% +$100K 1.75% 16
2022
Q2
$8.33M Buy
158,804
+73,281
+86% +$3.73M 1.9% 14
2022
Q1
$4.43M Sell
85,523
-5,126
-6% -$266K 0.86% 42
2021
Q4
$5.35M Sell
90,649
-261
-0.3% -$12.9K 0.97% 38
2021
Q3
$3.91M Sell
90,910
-2,378
-3% -$105K 0.75% 48
2021
Q2
$3.65M Sell
93,288
-962
-1% -$37.4K 0.7% 53
2021
Q1
$3.42M Sell
94,250
-11,275
-11% -$400K 0.68% 51
2020
Q4
$3.88M Buy
105,525
+6,175
+6% +$227K 0.82% 48
2020
Q3
$3.46M Sell
99,350
-1,290
-1% -$45.2K 0.83% 48
2020
Q2
$3.12M Sell
100,640
-8,038
-7% -$273K 0.82% 48
2020
Q1
$3.37M Sell
108,678
-1,808
-2% -$61.6K 1.03% 39
2019
Q4
$4.11M Sell
110,486
-8,677
-7% -$309K 0.93% 42
2019
Q3
$4.06M Sell
119,163
-75,658
-39% -$2.75M 0.99% 42
2019
Q2
$8.01M Sell
194,821
-61,786
-24% -$2.45M 1.86% 16
2019
Q1
$10.3M Buy
256,607
+9,676
+4% +$388K 2.47% 9
2018
Q4
$10.2M Buy
246,931
+9,471
+4% +$393K 2.93% 6
2018
Q3
$9.93M Sell
237,460
-7,044
-3% -$271K 2.2% 12
2018
Q2
$8.42M Sell
244,504
-21,198
-8% -$724K 2.03% 18
2018
Q1
$8.95M Sell
265,702
-4,433
-2% -$152K 2.14% 15
2017
Q4
$9.28M Buy
270,135
+10,853
+4% +$370K 2.03% 17
2017
Q3
$8.78M Buy
259,282
+93,631
+57% +$3.01M 2% 16
2017
Q2
$5.28M Sell
165,651
-56,021
-25% -$1.77M 1.23% 31
2017
Q1
$7.2M Sell
221,672
-7,207
-3% -$227K 1.67% 24
2016
Q4
$7.05M Sell
228,879
-73,587
-24% -$2.25M 1.66% 22
2016
Q3
$9.72M Buy
302,466
+24,339
+9% +$814K 2.3% 13
2016
Q2
$9.29M Sell
278,127
-23,572
-8% -$752K 2.21% 11
2016
Q1
$8.48M Buy
301,699
+63,263
+27% +$1.81M 1.96% 16
2015
Q4
$7.3M Sell
238,436
-132,764
-36% -$4.18M 1.69% 21
2015
Q3
$11.1M Sell
371,200
-9,182
-2% -$294K 2.69% 5
2015
Q2
$12.1M Sell
380,382
-14,441
-4% -$471K 2.65% 5
2015
Q1
$13M Sell
394,823
-4,529
-1% -$144K 2.67% 7
2014
Q4
$11.8M Buy
399,352
+9,398
+2% +$269K 2.37% 7
2014
Q3
$10.9M Buy
389,954
+934
+0.2% +$26.2K 2.26% 8
2014
Q2
$11M Sell
389,020
-2,303
-0.6% -$65.6K 2.17% 8
2014
Q1
$11.9M Buy
391,323
+1,768
+0.5% +$52.7K 2.46% 8
2013
Q4
$11.3M Sell
389,555
-11,524
-3% -$335K 2.34% 8
2013
Q3
$10.9M Buy
401,079
+13,547
+3% +$369K 2.37% 10
2013
Q2
$10.3M Buy
+387,532
New +$10.7M 2.29% 11

Other funds holding PFE

Chemung Canal Trust's PFE Position: Q2 2026 in Review

Chemung Canal Trust reduced its Pfizer (PFE) stake by 5.4% in Q2 2026, selling an estimated $29K and leaving 19,262 shares worth $464K. The position accounts for 0.09% of the portfolio, ranked #89.

Chemung Canal Trust first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $13M in Q1 2015. 1,338 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Chemung Canal Trust held 19,262 shares of Pfizer worth $464K as of Q2 2026.
  • Chemung Canal Trust sold 1,110 Pfizer shares in Q2 2026, an estimated $29K.
  • Pfizer made up 0.09% of Chemung Canal Trust's portfolio in Q2 2026, its #89 holding.
  • Chemung Canal Trust first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • Chemung Canal Trust's Pfizer position peaked at $13M in Q1 2015.
  • 1,338 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Chemung Canal Trust's 13F filing for Q2 2026, filed 15 Jul 2026.